Alterity Therapeutics Announces Cessation of Securities Due to Unmet Conditions

Alterity Therapeutics ( (ATHE) ) has shared an announcement.

On June 30, 2025, Alterity Therapeutics announced the cessation of certain securities due to unmet conditions. Specifically, 4,250,000 options expiring on November 29, 2026, with an exercise price of $0.0375, and 400,000 options expiring on the same date with an exercise price of $0.0238, have lapsed. This cessation was attributed to the resignation of an employee and the cessation of a contractor, impacting the company’s issued capital structure.

The most recent analyst rating on (ATHE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.

Spark’s Take on ATHE Stock

According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.

The overall stock score for Alterity Therapeutics is driven by financial performance challenges, including declining revenues, persistent losses, and negative cash flows. Technical analysis offers mixed signals, with a potential for support indicated by the 200-day moving average. However, valuation remains a concern due to negative earnings and lack of dividends, leading to an overall unattractive investment profile at this time.

To see Spark’s full report on ATHE stock, click here.

More about Alterity Therapeutics

Alterity Therapeutics Limited is a development stage enterprise in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases. The company is headquartered in Melbourne, Australia, and is listed on the Australian Securities Exchange (ASX) under the code ATH.

Average Trading Volume: 44,398

Technical Sentiment Signal: Buy

Current Market Cap: $59.64M

Learn more about ATHE stock on TipRanks’ Stock Analysis page.